PMID: 9169308Apr 1, 1997Paper

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
P DostertI Poggesi

Abstract

The pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor, in humans and animal models are reviewed here. Reboxetine has potent antidepressant activity, low affinity for alpha-adrenergic and muscarinic receptors and low toxicity in animals. It is a mixture of (R,R) and (S,S) enantiomer, the latter being more potent but no qualitative differences in pharmacodynamic properties are observed between the two. Humans rapidly absorb reboxetine (tmax about 2 h) with a terminal half-life of elimination (t1/2) of 13 h, allowing twice-daily administration. Animal models also rapidly absorb reboxetine (tmax 0.5-2 h) but t1/2 was 1-2 h. Food does not affect bioavailability. There were no major inter-species differences in the metabolic profile of reboxetine. Elimination is principally renal in humans and monkeys. Reboxetine has linear pharmacokinetics in young, healthy males for single doses of 1-5 mg and in elderly, female depressed patients (up to 4 mg b.i.d.). Multiple dosing, gender or liver insufficiency had no significant effects on the pharmacokinetics. Elderly (particularly frail elderly) patients and patients with severe renal impairment may need dose reduction. Reboxetine shows no clinically r...Continue Reading

References

Jul 1, 1991·European Journal of Drug Metabolism and Pharmacokinetics·G CocchiaraM Strolin Benedetti
Jan 1, 1991·Medicinal Research Reviews·R W FullerD W Robertson
Mar 1, 1990·Anesthesiology·C MeistelmanC Ecoffey
Aug 1, 1990·Naunyn-Schmiedeberg's Archives of Pharmacology·W Daniel, K J Netter
Feb 1, 1990·British Journal of Clinical Pharmacology·B T VeeringJ Spierdijk
Jul 1, 1987·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·M SetoguchiY Maruyama
May 1, 1986·The Journal of Pharmacy and Pharmacology·W Daniel, M Melzacka
Jun 1, 1987·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·H KamimuraS Kageyama
Nov 1, 1986·Journal of Pharmaceutical Sciences·J Mordenti
Nov 1, 1980·Gastroenterology·R V PatwardhanK V Speeg
Apr 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·H Boxenbaum
Aug 1, 1995·Biopharmaceutics & Drug Disposition·D M EdwardsM Strolin Benedetti
Apr 1, 1995·British Journal of Clinical Pharmacology·R OrlandoP Palatini
Jan 1, 1995·Chirality·M Strolin BenedettiP Dostert
Apr 1, 1993·Pharmacogenetics·M L Dahl, L Bertilsson
Jan 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M V RudorferW Z Potter
Mar 1, 1993·Clinical Pharmacokinetics·J van Harten
Jan 1, 1995·Pharmacology & Therapeutics·B K ParkN R Kitteringham
Feb 1, 1996·British Journal of Clinical Pharmacology·S V OttonE M Sellers
Jan 1, 1997·Chirality·E FrigerioP Dostert
Jun 6, 2000·International Journal of Clinical Pharmacology and Therapeutics·I PoggesiJ C Fleishaker
Dec 1, 1993·British Journal of Clinical Pharmacology·V MartinelliM Del Zompo

❮ Previous
Next ❯

Citations

Jun 26, 2001·European Journal of Drug Metabolism and Pharmacokinetics·J F BergmannJ M Ségrestaa
Sep 19, 2008·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Magnus SchouChrister Halldin
Jun 5, 2002·European Journal of Pharmacology·Catherine VilpouxJean Costentin
Mar 5, 2008·Journal of Child and Adolescent Psychopharmacology·Paz TorenNathaniel Laor
Jan 26, 2011·Journal of Cognitive Neuroscience·Steffen GaisJan Born
May 12, 2000·Journal of Clinical Pharmacology·F CoulombP Duchêne
Mar 17, 2010·Molecular Neurodegeneration·Marwa AboukhatwaYuan Luo
May 14, 2003·Biological Psychiatry·Silvia GrappiCarla Gambarana
Oct 31, 2014·Biomedical Chromatography : BMC·R Nageswara Rao, K Guru Prasad
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S KasperE Hilger
Jan 3, 2013·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Tjerk BuetersJohan Bylund
Apr 22, 2017·The International Journal of Neuropsychopharmacology·Hsiao-I KuoMichael A Nitsche
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·D BaldwinM Lagnado
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·M Quasim, A Kumar
Jul 23, 2003·Journal of Psychopharmacology·Wai S Tse, Alyson J Bond
Jan 5, 2000·Journal of Geriatric Psychiatry and Neurology·V AndreoliG Vantini
Mar 23, 1999·Biopharmaceutics & Drug Disposition·J C FleishakerI Poggesi
Sep 1, 2004·Journal of Psychiatric Practice·Sheldon H Preskorn
Oct 28, 2017·Drugs·Jianyuan DengTai Ning Lam
Jan 26, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefania PariniRoberto W Invernizzi
Jun 6, 2007·The Pharmacogenomics Journal·D Tomalik-ScharteJ Kirchheiner
Feb 3, 2006·Scandinavian Journal of Urology and Nephrology·Tryggve Nevéus
Oct 31, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Thomas C BaghaiHans-Jürgen Möller
Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Anthony S RauhutMichael T Bardo
Oct 16, 1999·Therapeutic Drug Monitoring·A AvenosoE Spina

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved